RVTY · Revvity, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted operating profit margin non-GAAP | 28.9% | the second quarter of 2026 | — |
|
|
|||
| Diagnostics adjusted operating profit margin non-GAAP | 30.4% | the second quarter of 2026 | — |
|
|
|||
| Diagnostics pro forma organic revenue growth non-GAAP | 11% | the second quarter of 2026 | — |
|
|
|||
| Life Sciences adjusted operating profit margin non-GAAP | 31.1% | the second quarter of 2026 | — |
|
|
|||
| Life Sciences pro forma organic revenue growth non-GAAP | -3% | the second quarter of 2026 | — |
| Pro forma adjusted EPS from continuing operations non-GAAP | $1.41 | the second quarter of 2026 | — |
| Pro forma organic revenue growth non-GAAP | 3% | the second quarter of 2026 | — |
|
|
|||
| Pro forma revenue growth | 4% | the second quarter of 2026 | — |
| Diagnostics organic revenue growth | 4% | Q1 2026 | — |
| Life Sciences organic revenue growth | 3% | Q1 2026 | — |
| Organic revenue growth | 3% | Q1 2026 | — |
| Organic revenue growth from continuing operations | 4% | Q4 FY2025 | — |
| Reported revenue growth from continuing operations | 6% | Q4 FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVTY
this stock
Revvity, Inc.
|
$12.85B | +19.1% | -13.5% | 55.4 | 6.7% |
|
TMO
Thermo Fisher Scientific Inc.
|
$212.25B | -0.1% | +0.4% | 30.9 | 1.4% |
|
DHR
Danaher Corp /De/
|
$140.36B | -12.4% | +8.5% | 35.4 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$45.83B | -13.6% | +10.4% | 40.9 | 2.7% |
|
A
Agilent Technologies, Inc.
|
$39.85B | +4.3% | +6.4% | 28.3 | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVTY | +1.5% | +5.3% | +13.9% | +2.2% | +19.1% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -4.1% | +2.0% | +2.7% | -0.8% | +6.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.